Biomarkers or other assessment tools

This is a request for 2-page Letters of Intent to submit proposals concerning biomarkers or other assessment tools to the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Proposals concerning PET ligands for AD, fluid biomarkers for AD, and digital assessments including cognitive testing for AD are of particular interest, but an LOI for any assessment in other areas is welcome. Send LOI to and all questions should be directed to the same email address.


ADNI, founded in 2004, is a large multicenter public/private partnership grant funded by the National Institute on Ageing, industry, and non-profit foundations. The grant is awarded to the Northern California Institute for Research and Education (NCIRE) in San Francisco. The Principal Investigator is Michael W Weiner MD. The goal of ADNI is to validate and standardize biomarkers for Alzheimer disease (AD) clinical trials. ADNI has enrolled over 2000 participants who have been followed longitudinally. ADNI makes all data and samples publicly available, resulting in over 2300 publications. The ADNI leadership is now planning a renewal of its NIA grant which will be due in September 2021. The planning process has been initiated. The ADNI leadership is interested in receiving proposals from industry, non-profit, and academic organisations who have biomarkers (especially PET ligands, fluid biomarker assays, digital biomarkers/cognitive testing etc.) and other assessment tools which could be used in the next phase of ADNI which would begin August 2022. Letters of Intent (LOI) are due Dec 31, 2020 (LOIs after that date may be considered), but much earlier submissions are very strongly encouraged. Send LOI to and all questions should be directed to the same email address.

Visit funding web page